What does Barbie mean to a Black woman who was once 'the Black girl'?She reminds me that representation does not always come in the form of a person; sometimes, it's a doll that allows you to embrace ...

Clinical and Serological Characteristics of Type 3 APS, Isolated T1DM, and LADY/LADA: Unveiling Complex Interactions in Autoimmune Endocrinopathies Recent advancements in medical research have illuminated the intricate relationships between various autoimmune disorders, particularly as they pertain to endocrine dysfunction. A group of researchers led by Qiu Y. and collaborators has embarked on a profound exploration of such complexities, presenting a detailed study that highlights the clinical and serological characteristics of type 3 Autoimmune Polyglandular Syndrome (APS), isolated Type 1 Diabetes Mellitus (T1DM), and LADA/LADY (Latent Autoimmune Diabetes in Adults).

YouTube video by Occupy Democrats

Tirzepatide reduced weight, A1c, and insulin dose in type 1 diabetes in a small randomized controlled trial.

Author: Brian Rifkin, MDHattiesburg ClinicHattiesburg, MSCare of patients with diabetes has advanced significantly since Banting and Best discovered insulin over a century ago. The prognosis of type 1...

Regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance and sustaining immunological homeostasis. Emerging evidence indicates that Treg characteristics and functional alterations can significantly contribute to the pathogenesis of autoimmune diseases including type 1 diabetes mellitus (T1DM). Notably, recent studies have established a positive correlation between diminished numbers of Tregs and the onset of T1DM. Although targeting Tregs has emerged as an attractive therapeutic strategy for T1DM, the heterogeneity and mechanistic complexities of Tregs remain largely unexplored and limit clinical success. We explore the dynamic alterations of Treg frequencies and phenotypes, and discuss their regulatory mechanisms throughout T1DM progression. Furthermore, we provide an overview of preclinical studies and clinical trials targeting Tregs in T1DM. By addressing translational challenges and current limitations in clinical efficacy, the ultimate aim is to develop innovative immunotherapeutic interventions for T1DM.